Source link : https://www.newshealth.biz/health-news/novel-jak1-inhibitor-reduced-treatment-failures-in-active-noninfectious-uveitis/
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed. Though the trial was stopped early, 37.5% of patients with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis who received filgotinib experienced treatment failure by week 24 compared […]
Author : News Health
Publish date : 2024-07-19 17:49:39
Copyright for syndicated content belongs to the linked Source.
Categories